Why the study?
Does a drug-eluting absorbable metal scaffold (DREAMS) demonstrate long-term safety and performance in patients with de novo coronary lesions?
Does a drug-eluting absorbable metal scaffold (DREAMS) demonstrate long-term safety and performance in patients with de novo coronary lesions?
Answers are grounded in this paper and cite their sources.
The DREAMS drug-eluting absorbable metal scaffold demonstrated excellent long-term safety at three years with a low target lesion failure rate and no scaffold thrombosis in a first-in-man study.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Petronio et al. (2016) studied De novo coronary lesions (n=46). Drug-eluting absorbable metal scaffold (DREAMS) was evaluated on Target lesion failure (TLF) at three years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: